Skip to the content

About Biosimilar Development

Biosimilar Development is where stakeholders come to discover the most important trends and technologies involved in commercializing biosimilars. Content in this community covers new business models, payer negotiation strategies, market dynamics, and lessons from regulatory and reimbursement practices overseas, and more.

9,000+

Monthly Unique Users

18,000+

Monthly Page Views

50,000+

Leads Generated Through Partner Content In 2020

Our Readers

Our readers are directors, managers, bench level professionals, and executives who work in Manufacturing, Development, Regulatory, and the C-Suite. They are experts in topics including process, chromatography, drug safety and efficacy, regulatory and legislative actions, and more.

Other Recommended Communities

Our Clients

Community Resources

Editorial Themes

We believe in publishing the advice that helps our readers get their drugs and therapies to patients faster  - the kinds of content that can't be slotted into a monthly editorial calendar. Instead, here's an overview of the topics frequently published in this community.

Media Kit

We don't have one! We believe media kits are relics of the old-school B2B publishing model. B2B sales and marketing has changed drastically since our company was founded nearly 40 years ago. The way we produce and deliver information to our readers has changed too. Media kits have been replaced by the data-driven, highly customized products, services, and content we produce for our increasingly sophisticated strategic partners. Instead, we ask that you connect with us to learn more about how we drive business outcomes beyond vanity metrics and cold leads. You can read more about why we don't publish media kits on our Follow Your Buyer site - an online community dedicated to our methodology of engaging your buyers.

Let's work together.

Whether you're ready to hit the ground running or just starting and have questions, we're here to understand your goals and explore how we can help you.